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Abstract The present study was designed to investigate the
hypothesis that interleukin-4 (IL-4) can induce apoptosis of
human endothelial cells and to study regulatory pathways of this
process. Indeed, DNA ladder assay and flow cytometry study
showed that IL-4 can induce apoptosis of endothelial cells in a
time- and dose-dependent manner. In addition, IL-4 markedly
increased activity of caspase-3, and inhibition of this enzyme
suppressed IL-4-induced apoptosis in a dose-dependent manner.
These results provide the first evidence that IL-4 can induce
apoptosis of human endothelial cells. In addition, the data
indicate that the caspase-3-dependent pathway is critically
involved in this process. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Apoptosis of vascular cells can be involved in the progres-
sion of atherosclerosis [1^3]. For example, apoptotic cells can
be detected in neointima of atherosclerotic vessels, suggesting
that apoptosis might participate in remodeling of the vessel
wall during atherogenesis [2]. Endothelial cells may undergo
apoptosis in response to the proin£ammatory cytokines pro-
duced by activated macrophages and T-lymphocytes as a con-
sequence of the ongoing local immune and in£ammatory re-
sponse characteristic of atherogenesis [4]. Selected cytokines,
such as interleukin-1L (IL-1L), tumor necrosis factor-K (TNF-
K) or interferon-Q, can promote apoptosis of endothelial cells
[5,6].
Interleukin-4 (IL-4) is a pleiotropic immunomodulatory cy-
tokine secreted by T-helper 2 (TH2) lymphocytes, eosinophils,
and mast cells [7,8]. Normally, IL-4 promotes the di¡erentia-
tion of premature lymphocytes to the TH2 subset and induces
immunoglobulin class switching in B-lymphocytes. In addi-
tion, IL-4 is present at high levels in tissues of patients with
chronic in£ammatory diseases [9], including atherosclerosis
[10]. Evidence indicates that IL-4 may play a role in athero-
genesis through induction of in£ammatory responses, such as
upregulation of vascular cell adhesion molecule-1 (VCAM-1)
[11]. IL-4 also can synergize IL-1L, TNF-K or lipopolysachar-
ide (LPS)-induced VCAM-1 gene expression in endothelial
cells [12^14]. Although recent evidence suggests that IL-4
can induce apoptosis of cancer cells [15], the possible involve-
ment of this cytokine in apoptotic death of endothelial cells is
unknown.
Intracellular proteases are enzymes critically involved in ap-
optotic cell death. Caspase-3, also known as CPP32, is a
member of the IL-1L converting enzyme family of cysteine
proteases [16]. Caspase-3 is composed of 17 and 12 kDa sub-
units derived from a common enzyme, pro-caspase-3 [17,18],
and it cleaves substrates at aspartate residues. Induction of
caspase-3 proteolytic activity appears to be one of the most
important events in apoptosis [19,20]. In addition, caspase-3-
mediated apoptosis may be modulated by cellular oxidative
stress. For example, an increase in caspase-3-like protease
activity in human endothelial cells was associated with the
induction of apoptosis by oxidized LDL [21]. Because expo-
sure of endothelial cells to IL-4 also can increase cellular
oxidation [22], it is possible that caspase-3 may be activated
by this cytokine. Therefore, the aim of the present study was
to study the hypothesis that IL-4 can induce apoptosis of
human endothelial cells through the caspase-3-dependent
pathway.
2. Materials and methods
2.1. Cell culture and reagents
Human umbilical vein endothelial cells (HUVEC) were isolated
and cultured as described previously [23]. Cells were determined
to be endothelial by their cobblestone morphology and uptake of
£uorescent-labeled acetylated LDL (1,1P-dioctadecyl-3,3,3P3P-tetra-
methyl-indocarbocyanine perchlorate; Molecular Probes Inc., Eugene,
OR, USA). HUVEC from passage 2 were used in the present
study. Recombinant human IL-4 was purchased from RpD
Systems (Minneapolis, MN, USA). Z-Val-Ala-Asp-£uoromethyl-
ketone (zVAD-fmk) was purchased from Calbiochem (La Jolla, CA,
USA).
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2.2. DNA ladder assay
Treated HUVEC were collected by trypsinization and suspended in
100 Wl of lysis bu¡er containing 50 mM Tris^HCl, pH 7.5, 20 mM
EDTA, and 1% NP-40. After centrifugation (3000 rpm, 5 min), super-
natants were collected and treated with 1% sodium dodecyl sulfate
and RNase A (5 mg/ml) for 2 h at 56‡C, followed by proteinase K
(2.5 mg/ml) for 2 h at 37‡C. The samples were mixed with 0.5 volume
of 10 M ammonium acetate and 2.5 volumes of ice-cold ethanol, and
incubated for 1 h at 380‡C. The DNA was precipitated by centrifu-
gation (12 000 rpm, 20 min), washed with 80% ice-cold ethanol, air-
dried, and resuspended in 50 Wl of TE bu¡er. Aliquots of 4 Wg of
cellular DNA were fractionated by electrophoresis on a 2% agarose
gel. After staining with SYBR0 Green I (Molecular Probes, Eugene,
OR, USA), the internucleosomal DNA cleavage (DNA laddering) was
visualized using phosphoimaging technology (FLA-2000, Fuji, Stam-
ford, CN, USA).
2.3. Flow cytometry (annexin V staining)
Annexin V binding was measured using a commercially available
kit (Annexin-V-FLUOS; Roche Molecular Biochemicals, Indianapo-
lis, IN, USA) according to the manufacturer’s recommendations. The
positive binding was determined using a FACSCalibur £ow cytometer
(Becton Dickinson, San Jose, CA, USA).
2.4. Caspase-3 activity assay
Caspase-3 activity in cell extracts was measured using a Caspase-3
Cellular Activity Assay kit PLUS (Biomol, Plymouth Meeting, PA,
USA). Brie£y, cells were collected and lysed in an ice-cold lysis bu¡er
containing 50 mM HEPES at pH 7.4, 1 mM dithiothreitol (DTT), 0.1
mM EDTA, 0.1% CHAPS, and 0.1% NP-40. The cell lysate was
centrifuged at 10 000Ug for 5 min at 4‡C and the supernatant fraction
was used to quantitate caspase-3 activity. Aliquots of 20 Wg of cell
lysate protein were incubated for 1 h at 37‡C in assay bu¡er contain-
ing 50 mM HEPES at pH 7.4, 100 mM NaCl, 10 mM DTT, 1 mM
EDTA, 0.1% CHAPS, 10% glycerol and 0.2 mM Ac-Asp-Glu-Val-
Asp-p-nitroaniline substrate. The amount of p-nitroaniline released
by caspase-3 activity was quantitated by measuring the optical density
at 405 nm. Caspase-3 activity was expressed as pmol p-nitroaniline
released per min per Wg cellular protein.
2.5. Statistical analysis
Routine statistical analysis of data was completed using SYSTAT
7.0 (SPSS Inc., Chicago, IL, USA). One-way ANOVA was used to
compare mean responses among the treatments. For each endpoint,
the treatment means were compared using Bonferroni least signi¢cant
di¡erence procedure. Statistical probability of P6 0.05 was consid-
ered signi¢cant.
3. Results
3.1. IL-4 can induce endothelial cell apoptosis
To determine whether IL-4 can induce endothelial cell ap-
optosis, DNA fragmentation was studied after exposure of
HUVEC to IL-4. As shown in Fig. 1, IL-4 in the presence
of cycloheximide (CHX), which inhibits protein synthesis,
dramatically induced internucleosomal DNA fragmentation.
Signi¢cant DNA laddering was detected as early as 2 h after
treatment with 10 ng/ml of IL-4 and reached maximum after a
4 h exposure to this cytokine (Fig. 1A).
E¡ects of di¡erent doses of IL-4 on DNA fragmentation
are shown in Fig. 1B. DNA laddering was observed in cells
treated with IL-4 at the dose of 1 ng/ml. Exposure of HUVEC
to 10 ng/ml of IL-4 caused a slightly more markedly DNA
fragmentation as compared to 1 ng IL-4/ml. However, an
increase in IL-4 dose to 50 ng/ml did not further potentiate
internucleosomal DNA fragmentation.
Flow cytometry analysis was performed to con¢rm that IL-
4 can induce endothelial cell apoptosis. The appearance of
phosphatidylserine in the outer lea£et of the plasma mem-
brane, as measured by binding of FITC-labeled annexin V,
was increased in cells incubated with IL-4 in a dose-dependent
manner as compared to controls (Fig. 2A). Treatment of en-
dothelial cells with IL-4 changed the percentage of apoptotic
cells from 22.2 þ 7.4% (control cultures) to 31.5 þ 1.62% (0.1
ng IL-4/ml), 44.8 þ 1.66% (1.0 ng IL-4/ml), and 42.9 þ 2.30%
(10 ng IL-4/ml). Fig. 2B shows typical examples of histograms
obtained in HUVEC treated with di¡erent doses of IL-4 as
well as in control cells. In IL-4-treated cultures, populations
of apoptotic cells were markedly distinguished from the over-
all cell population.
3.2. Caspase-3 pathway is involved in IL-4-induced endothelial
cell apoptosis
To identify the regulatory pathways of endothelial cell ap-
optosis induced by IL-4, activity of caspase-3 was measured in
HUVEC treated with this cytokine for 4 h. As indicated in
Fig. 3, exposure to IL-4 resulted in a dose-dependent increase
in caspase-3 activity. To further prove involvement of cas-
pase-3 in IL-4-induced apoptosis of endothelial cells, HUVEC
Fig. 1. IL-4 induces apoptosis of human endothelial cells. HUVEC
were incubated with or without CHX (10 Wg/ml) for 0.5 h and ex-
posed to 10 ng/ml of IL-4 for the indicated time (A). In parallel ex-
periments, HUVEC were treated with di¡erent doses of IL-4 for 4 h
(B). Following treatment exposures, DNA was extracted, fractionat-
ed by 2% agarose gel electrophoresis and visualized using phospho-
imaging technology. M, molecular weight markers (100 bp DNA
ladder).
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were pretreated with zVAD-fmk, a speci¢c inhibitor of this
enzyme, before exposure to 10 ng/ml of IL-4. Fig. 4 indicates
that zVAD-fmk markedly reversed the ability of IL-4 to in-
duce endothelial cell apoptosis in a dose-dependent manner.
Indeed, the IL-4-induced apoptosis of HUVEC was com-
pletely prevented by pretreatment with 100 WM of this inhib-
itor.
Fig. 2. A: Annexin V binding to human endothelial cells in re-
sponse to IL-4 as detected by £ow cytometry. HUVEC were pre-
treated with CHX (10 Wg/ml) for 0.5 h and exposed to the indicated
amounts of IL-4 for 4 h. Data are expressed as mean þ S.D. *Statis-
tically signi¢cant as compared to the control group (P6 0.05).
B: Representative histograms of annexin V binding to human endo-
thelial cells in response to IL-4. HUVEC were treated as indicated
to the legend to A. Populations of apoptotic cells are indicated by
vertical bars.
Fig. 3. Dose-dependent increase in caspase-3 activity in human en-
dothelial cells in response to IL-4. HUVEC were pretreated with
CHX (10 Wg/ml) for 0.5 h and exposed to the indicated amounts of
IL-4 for 4 h. Data are expressed as mean þ S.D. *Statistically signi¢-
cant as compared to the control group (P6 0.05).
Fig. 4. Inhibition of caspase-3 prevents IL-4-induced apoptosis of
human endothelial cells. HUVEC were pretreated with the indicated
concentrations of zVAD-fmk for 2 h, incubated with CHX (10 Wg/
ml) for 0.5 h, and exposed to IL-4 (10 ng/ml) for 4 h. Following
treatment exposures, DNA was extracted, fractionated by 2% aga-
rose gel electrophoresis and visualized using phosphoimaging tech-
nology. M, molecular weight markers (100 bp DNA ladder).
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4. Discussion
Results of the present study provide compelling evidence
that IL-4 induces apoptosis of cultured endothelial cells via
caspase-3-dependent pathway(s). Apoptosis has been charac-
terized biochemically by the cleavage of genomic DNA into
nucleosomal fragments of 180 bp or their multiples. These
fragments are readily detected as a DNA ladder by agarose
gel electrophoresis and, in fact, such a ladder pattern has been
regarded as the most characteristic hallmark of apoptosis [24^
26]. Therefore, to study endothelial cell apoptosis, we eval-
uated internucleosomal DNA fragmentation by assessing the
size of DNA isolated from IL-4-treated and untreated HU-
VEC. Typical internucleosomal DNA fragments appeared in
HUVEC treated with IL-4 in the presence of CHX. These
results are consistent with previous studies, which have dem-
onstrated that inhibition of protein synthesis may be required
to promote complete DNA fragmentation of vascular endo-
thelial cells. For example, a variety of stimuli including IL-1L,
LPS, and TNF-K have been reported to induce endothelial
cell apoptosis in the presence of a protein synthesis inhibitor
[5,6,27]. Results of these studies, including current research
report, suggest that inducible or constitutive cytoprotective
proteins control endothelial cell survival.
Apart from DNA fragmentation, rearrangements of cellular
plasma membranes are another marker of apoptotic cell
death. Indeed, in the early stages of apoptosis, phosphatidyl-
serine is translocated from the plasma membrane inner lea£et
to the outer lea£et where it triggers recognition and phagocy-
tosis of the apoptotic cells [28,29]. Annexin V is a Ca2-de-
pendent phospholipid binding protein with high a⁄nity for
phosphatidylserine. Therefore, £ow cytometry analysis of an-
nexin V binding was used as a sensitive marker of apoptotic
cell death [28,30^32]. Results of these studies con¢rm that IL-
4 can markedly induce apoptosis of human endothelial cells in
the presence of CHX. Because the endothelium controls sev-
eral vital functions of the vascular endothelium, such as vas-
cular permeability, tone, homeostasis, and in£ammatory re-
sponses [33], apoptosis of endothelial cells can signi¢cantly
a¡ect normal metabolism of the vessel wall. In addition, ap-
optosis can contribute to endothelial cell loss, a prominent
feature of atherosclerosis, and apoptotic endothelial cells ex-
press marked pro-coagulatory properties [3].
Caspases have been recognized to play a major role in the
execution of apoptosis induced by a variety of stimuli [34].
They are normally present as inactive zymogens in the cellular
cytoplasm, and their activation during cell apoptosis is
achieved hierarchically, so that activation of the upstream
members of this family initiates the caspase cascade by cleav-
age and subsequent activation of downstream caspases [35].
Among individual members of the caspase family, it appears
that caspase-3 is critically involved in apoptosis. In fact, re-
cent evidence provides a direct link between caspase-3 activa-
tion and DNA fragmentation. It was demonstrated that the
cytosolic endonuclease CAD (caspase-activated deoxyribonu-
clease) or DFF40 (DNA fragmentation factor, 40 kDa sub-
unit) is activated as a result of caspase-3-catalyzed cleavage of
the associated inhibitor ICAD or DFF45 [19,36,37]. Our ¢nd-
ings, especially with the speci¢c caspase-3 inhibitor (Fig. 4),
con¢rm that caspase-3 activation by IL-4 is involved in the
regulatory pathway of endothelial cell apoptosis induced by
this cytokine.
In summary, the present study provides the ¢rst evidence
that IL-4 can induce apoptosis of human vascular endothelial
cells. In addition, the data indicated that the caspase-3-depen-
dent pathway is critically involved in this process.
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